School of Pharmacy and Pharmaceutical Sciences 2024-25 Annual Report

SCHOOL OF PHARMACY AND P H ARMACE U T I C A L SC I E N CES

2024-2025 ANNUAL REPORT

2024-2025 ANNUAL REPORT: DEAN’S MESSAGE

Binghamton University’s School of Pharmacy and Pharmaceutical Sciences has achieved significant milestones and celebrated remarkable successes over the past year. It is with great pride that I reflect on the outstanding contributions of our faculty, staff and students, whose dedication continues to elevate our school and its impact on the profession.

A few highlights from the past year include:

• Exceptional post-graduate achievements, with students securing prestigious industry fellowships, PGY1 residencies and PGY2 residencies.

• Faculty members earning regional and national recognition for their excellence in education, research and clinical practice through awards from organizations such as APhA, ACCP and AACP.

• A notable distinction of two of our faculty members being ranked among the Top 2% of researchers worldwide in their field, as recognized by Stanford University.

• The successful graduation of the second cohort of pharmacy technicians, addressing the critical shortage of skilled professionals in the Greater Binghamton area.

This annual report provides a comprehensive overview of our faculty’s impactful research presentations, publications and funding achievements, highlighting the innovation and dedication that defines our school.

We are proud of these accomplishments and remain steadfast in our commitment to advancing pharmacy education, fostering innovation and nurturing the next generation of pharmacy professionals. Together, we are building a future of excellence and impact.

Sincerely,

Kanneboyina Nagaraju, DVM, PhD

Dean and SUNY Distinguished Professor, School of Pharmacy and Pharmaceutical Sciences

Presentations (July

1, 2024–June 30, 2025)

Aaron Beedle, PhD

Platform Presentation: Chahine EB, Matsumoto RR, Beedle AM, Carter CW, Clem JR, Nuziale B, Tromp KM, Woods ZT. “I Choose Pharmacy Because? Reaching and Welcoming New Audiences to the Pharmacy Profession.” Presentation by the members of the 2023-2024 AACP Student Affairs Committee. American Association of Colleges of Pharmacy Annual Meeting, Boston, Mass. 2024.

KarenBeth Bohan, PharmD

Poster Presentation: Ryan M, Cheung N, Bohan K. “Empowering Pharmacists through FIP AcPS Scholarship Workgroup 2019 – 2024.” International Pharmaceutical Federation World Congress; Sept. 2024, Cape Town, South Africa.

Virtual Certificate Program Presentation: Bohan, K. “Journal Scope, Impact Factor, and Citations: Considerations when Selecting a Journal to Share Your Work.” Presentation is part of the Binghamton University and Upstate University Hospitals Research Certificate Program. March 4, 2025.

Keynote Presentation: Bohan, K. “The Importance of PharmD’s and the Pharmacists Role in the Hospital.” Presented this keynote lecture at the PharmD New Student Orientation at Nirma University Institute of Pharmacy, Ahmedabad, Gujarat, India. July 29, 2024.

Platform Presentation: Bohan, K. “Introduction to Pharmaceutical Care and Pharmacy Careers.” Presented to pharmacy students and faculty at Nirma University Institute of Pharmacy, Ahmedabad, Gujarat, India. July 30, 2024.

Platform Presentation: Bohan, K. “Antimicrobial Stewardship Workshop.” Presented to pharmacy students at Sri Vishu College of Pharmacy, Bhimavaram, Andra Pradesh, India. Aug. 5, 2024.

Tracy Brooks, PhD

Platform Presentation: Brooks, T. Invited presentation. CERM 2024, ACS Local Meeting, Pittsburgh, Penn. Nov. 8, 2024.

Platform Presentation: Brooks, T. Invited presentation. G4 Nucleic Acid Conference, Minneapolis, Minn. June 2-6, 2025.

Platform Presentation: Brooks, T. Invited presentation. GRS and GRC NNO, Newport, R.I. July 6-10, 2025.

Leon Cosler, PhD

Poster Presentation: Haykal M, Kalabanka J, McCormack A, Graterol J, Sotomayor B, Cosler L. “Examining the Association Between GLP1 Agonists and Suicidal Thoughts: An Analysis of MEPS data 2018-2021.” American Society of Health-System Pharmacists Midyear Clinical Meeting 2024, New Orleans, La. Dec. 9, 2024.

Tony D. Davis, PhD

Poster Presentation: Murray R, Jahan N, Zipkowitz S, Martin A, Davis TD, and Redman WK. “Enzyme and Antibiotic Combinations to Treat BiofilmAssociated Infections: Friend or Foe?” Annual Biomedical Research Conference for Minoritized Scientists (ABRCMS). Pittsburgh, Penn. November 2024.

Poster Presentation: Lalla J and Davis TD “Discovery of Mycobacterial Prokaryotic UbiquitinProteasome System PafA Ligand Binding Sites Using Covalent Chemical Probes.” American Society of Health Systems Pharmacists (ASHP) Midyear Clinical Meeting. New Orleans, La. December 2024.

Poster Presentation: McKay, SJ, Brooks TA, and Davis TD. “Design, Synthesis, and Evaluation of MYC Pathway Targeting Degraders for the Treatment of Pancreatic Cancer.” Keystone Conference on Proximity-Based Therapeutics: Targeted Protein Degradation and Other Pharmacological Approaches. Santa Fe, N.M. February 2025.

Platform Presentation: Davis TD. “Tools to Interrogate Nonribosomal Peptide and Polyketide Methyl Transferase Substrate and Carrier Protein Recognition.” University of Minnesota Chemical Biology Colloquium. Minneapolis, Minn. March 2025.

Platform Presentation: Davis TD. “Tools to Interrogate Nonribosomal Peptide and Polyketide Methyl Transferase Substrate and Carrier Protein Recognition.” Wayne State University Department of Chemistry Seminar. Detroit, Mich. May 2025.

Poster Presentation: Fruitwala A, Watson D, and Davis TD. “Unveiling the Function of a Potential Pseudomonas aeruginosa Drug Target Through Fluorescence Thermal Shift Assays.” New York Academy of Sciences Chemical Biology Discussion Group Year End Symposium. New York, N.Y. May 2025.

Poster Presentation: Lam DM, Valencia-Castaneda A, Thompson R, and Davis TD. “Mapping the Interfaces of the Pseudomonas aeruginosa PchF Methyltransferase.” New York Academy of Sciences Chemical Biology Discussion Group Year End Symposium. New York, N.Y. May 2025.

Poster Presentation: Martin AE and Davis TD “Synthesis of Yersiniabactin Analogues to Probe Methyltransferase Substrate Selectivity During Biosynthesis.” New York Academy of Sciences Chemical Biology Discussion Group Year End Symposium. New York, N.Y. May 2025.

Poster Presentation: McKay SJ, Brooks TA, and Davis TD. “Design, Synthesis, and Evaluation of MYC Pathway Targeting Degraders for the Treatment of Pancreatic Cancer.” New York Academy of Sciences

Chemical Biology Discussion Group Year End Symposium. New York, N.Y. May 2025.

Poster Presentation: Tiszler JX, Davis TD, and Brooks TA. “Targeting the CDK4/6 and Bcl-2 Pathways in Mantle Cell Lymphoma.” New York Academy of Sciences Chemical Biology Discussion Group Year End Symposium. New York, N.Y. May 2025.

Katie Edwards, PhD

Platform Presentation: Edwards K. “Thiamine Deficiency from a One Health Perspective.” Invited oral presentation, Cornell University, Ithaca, N.Y. Nov. 14, 2024.

Yuan Fang, PhD

Poster Presentation: Fang Y and Han J. “Impact of immigration timing on medication nonadherence and cognitive function in older adults.” The Gerontology Society of America (GSA) 2024 Annual Scientific Meeting, Seattle, Wash. November 2024.

Platform Presentation: Fang Y. “Clustering microbiome data using mixtures of logistic normal multinomial models.” 2024 Joint Statistical Meetings (JSM), Portland, Ore. August 2024.

John Fetse, PhD

Poster presentation: Roundtree I, Altenor A, Valdivia R, St. Ignac T, Esposito A, DiazDavila K, Lamptey R, Fetse J. “Development of a smart nanocarrier system for prostate cancer immunotherapy.” American Association for Cancer Research (AACR) Annual Meeting. Chicago, Ill. April 25-30, 2025.

Elizabeth Hageman, PharmD

Poster Presentation: Hageman E, Brooks T. “Enhancing Oncology Infographic Evaluation: A Peer Calibration Approach.” American Association of Colleges of Pharmacy Annual Meeting Boston, Mass. July 2024.

Poster Presentation: Hageman E, Lynch SE. “From Admission to Gen Z: Describing the Career Interests and Motivations of High School Seniors Interested in Health Professions.” American Society of Health System Pharmacy Midyear Clinical Meeting. New Orleans, La. December 2024.

Platform Presentation: Hageman E, Kiles T, Malhotra A, Petrelli, H., Wenger B. “The AACP 2024 Cuba Delegation: Lessons Learned Regarding Globalizing Pharmacy Education through Collaboration and Cooperation.” Presented at the American Association of Colleges of Pharmacy Annual Meeting, Boston, Mass. July 2024.

Platform Presentation: Hageman E, Rewald M, Arnold J. “Empowering Tomorrow’s Technicians:

Fostering Partnerships with Academia to Develop Cutting-Edge Technician Training Programs.” Presented at American Society of Health System Pharmacy Midyear Clinical Meeting. New Orleans La. December 2024.

Yetrib Hathout, PhD

Invited speaker: Hathout Y. “Monitoring biomarkers for Duchenne muscular dystrophy.” Critical Path Institute, Tucson, Ariz. March 16, 2025.

Invited speaker: Hathout Y. “Biomarker Development for the Diagnosis and Prognosis of Lyme Disease.” Lyme Disease Conference organized by Southern Tier LYME Support, Inc. July 9, 2024.

Poster presentation: Canessa EH, Ojo BK, Spathis R, Novak JS, Hathout Y. “A novel IP-mass spectrometry method to characterize the dystrophin associated protein complex in skeletal muscle.” The American Society of Gene and Cell Therapy conference, The Westin Michigan Avenue Chicago, Chicago, Ill. Nov. 20, 2024.

Poster Presentation: Le KK, Canessa EH, Edwards K, Hathout Y. “Non-invasive Urinary Biomarker Discovery for Becker Muscular Dystrophy (BMD).” Muscular Dystrophy Association Annual Conference. Hilton Anatole, Dallas, Tex. March 16, 2025.

Poster Presentation: Samkutty S, CINRG DNHS investigators, FOR-DMD investigators of the Muscle Study Group, Guglieri M, Hathout Y. “Advanced metabolomic biomarker profiling for muscular dystrophinopathies.” Muscular Dystrophy Association Annual Conference. Hilton Anatole, Dallas, Tex. March 16, 2025.

Eric Hoffman, PhD

Poster Presentation: Hoffman E. “Screening of Treatment-Emergent Anti-Dystrophin Antibodies: A Validated, Regulatory-Compliant LIPS Assay Covering 100% of Dystrophin.” Breakthroughs in Muscular Dystrophy, Muscular Dystrophy Association and American Society for Cell and Gene Therapy. Chicago, Ill. November 2024.

Platform Presentation: Hoffman E. “The Venture Philanthropy Model of Drug Development - Working with Non-Profit Foundations and Governments from Concept to Drug Approval.” Breakthroughs in Muscular Dystrophy, Muscular Dystrophy

Association and American Society for Cell and Gene Therapy. Chicago, Ill. November 2024.

Rachel Klosko, PharmD

Poster Presentation: Yeung E, Campbell J, Goble E, Emick H, Lawson S, Rockwell R, Klosko R, Cahill J, and Reitknecht F. “Less is More; Optimizing Narcotic Use in Pain Management In Cardiovascular Surgery.” Acute Care Surgery (ACS) Quality and Safety Conference. Denver, Colo. July 2024.

Poster Presentation: Klosko R, Huang G, Krummenacker B, Major J, Reiver M, Strong K, Whittacker L, Saroka R, Sharma S. “Evaluation of major inpatient statin-drug interactions in inpatient older adults prescribed simvastatin compared to all other statins.” American College of Clinical Pharmacy (ACCP) Annual Meeting. Phoenix, Ariz. October 2024.

Wesley Kufel, PharmD

Poster Presentation: Naik H, Kufel WD, Spinler SA. “Impact of a Capstone Research Experience on Doctor of Pharmacy Post-Graduate Work Roles.” American College of Clinical Pharmacy (ACCP) Annual Meeting. Phoenix, Ariz. October 2024.

Poster Presentation: Kufel WD, Zeineddine N, Roenfanz H, Fouad A, Shields R, Hanrahan K, Kuti J. “Pharmacokinetic Evaluation of SulbactamDurlobactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration Infected with Carbapenem-resistant Acinetobacter baumanniicalcoaceticus.” American College of Clinical Pharmacy (ACCP) Annual Meeting. Phoenix, Ariz. October 2024.

Poster Presentation: Govel JC, Seabury RW, Asiago-Reddy EA, Gutierrez RL, Kufel WD “Evaluation of Shorter Versus Longer Antifungal Treatment Durations for Candida Urinary Tract Infections.” IDWeek 2024, Los Angeles, Calif. Oct. 18, 2024.

Poster Presentation: Davis MR, Kufel JE, Kufel WD, Ross J, Oleksiuk L, Ours R, Smith E, Pham C, Trisler M, Tverdek F. “Infectious Diseases Pharmacist Curbsides: Questions Infectious Diseases Providers Ask Infectious Diseases Pharmacists.” IDWeek 2024, Los Angeles, Calif. Oct. 18, 2024.

Poster Presentation: Caniff KE, Eubank TA, Garey KW, Krekel T, Kufel WD, Andrade J, Cerenzio J, Veve MP, Rybak MJ. “Patient Characteristics and Clinical Outcomes Associated with MeropenemVaborbactam Treatment in Carbapenem-Resistant Enterobacterales Pneumonia.” IDWeek 2024, Los Angeles, Calif. Oct. 18, 2024.

Poster Presentation: Caniff KE, Xhemali X, Tran N, Eubank TA, Garey KW, Guo Y, Chang M, Barber KE, Biagi M, Carlson T, Frens J, Krekel T, Venugopalan V, Kufel WD, Carr A, Hayes J, Sanders J, Chandler E, Li R, Justo JA, Antosz K, Benefield R, Moore WJ, Ross J, Hobbs A, Stefanos S, Mercuro N, Raux B, Zeitler K, Rybak MJ. “Evaluation of Imipenem-CilastatinRelebactam for Treatment of Pseudomonas aeruginosa Infections.” IDWeek 2024, Los Angeles, Calif. Oct. 18, 2024.

Poster Presentation: Carpenter A, Northup A, Sucuzhanay M, Terrell C, Thurston J, Seabury RW, Yang CJ, Kufel WD. “Evaluation of Asymptomatic Bacteriuria Treatment Among Renal Transplant Recipients.” American Society of Health-System Pharmacists Midyear Clinical Meeting 2024, New Orleans, La. Dec. 9, 2024.

Poster Presentation: Van Helden SR, Caniff KE, Judd C, Eubank TA, Garey KW, Kufel WD, Krekel T, Tan KK, Chandler EL, Aramburo JA, Chatterji D, Walker SD, Yost CN, Muscat JM, Andrade J, Cerenzio J, Raja K, Veve MP, Rybak MJ. “Clinical Use of Meropenem-Vaborbactam in CarbapenemResistant Enterobacterales or Pseudomonas aeruginosa Pneumonia.” European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria. April 15, 2025.

Poster Presentation: Al Musawa M, Kunz Coyne AJ, Judd C, Lucas K, Holger D, Slaton C, Shald E, Gabriela Cabanilla M, Kufel WD, Bleick C, Biagi M, Jankowski CA, White B, Molina K, Mynatt R, Eubank T, Rux CE, Wrenn RE, VanDorf S, Venugopalan V, Orzol C, Sassine J, Caniff KE, Kang-Birken SL, Morrisette T, Veve MP, Rybak MJ. “Race Against Time: Unraveling the Impact of Early CeftazidimeAvibactam Administration.” European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria. April 15, 2025.

Poster Presentation: Al Musawa M, Caniff KE, Rebold N, Xhemali X, Tran N, Eubank TA, Garey

KW, Guo Y, Chang M, Barber KE, Krekel T, Biagi M, Kufel WD, Carr A, Hayes J, Carlson TJ, Frens J, Venugopalan V, Lucas K, Coyne AK, Sanders J, Chandler E, Li R, Antosz A, Justo JA, Benefield R, Moore WJ, Ross J, Adams J, Albarillo F, Stefanos S, Hobbs A, Mercuro N, Raux B, Zeitler K, Rybak M. “Clinical Outcomes of Imipenem-CilastatinRelebactam in Obese Versus Non-Obese Patients.” Making a Difference in Infectious Diseases (MAD-ID) Annual Meeting, Orlando, Fla. May 29, 2025.

Poster Presentation: Al Musawa M, Caniff KE, Van Helden SR, Alosaimy S, Langf AM, Judd C, Scipione MR, Zhao JJ, Eubank TA, Garey KW, Kufel WD, Krekel T, Tan KK, Chandler EL, Aramburo JA, Chatterji D, Walker SD, Yost CN, Muscat JM, Andrade J, Cerenzio J, Raja K, Morrisette T, Jorgensen SCJ, Mynatt R, Carlson TJ, Allen D, DeRonde K, Vega AD, Abbo LM, Venugopalan V, Athans V, Saw S, Claeys KC, Miller M, Molina KC, Amaya L, Ortwine J, Davis SL, Veve MP, Rybak MJ. “Impact of Obesity on Clinical Outcomes in Patients Treated with Meropenem-Vaborbactam: A Multicenter Retrospective Cohort Study.” Making a Difference in Infectious Diseases (MAD-ID) Annual Meeting, Orlando, Fla. May 29, 2025.

Platform Presentation: Kufel WD, Paolino KM, Hathout Y. “Tick Season Webinar: Panel of Professionals Discuss Research, Prevention, and Treatment.” Assemblywoman Donna Lupardo and Broome County, Binghamton, N.Y. Aug. 22, 2024.

Platform Presentation: Kufel WD, Paolino KM. “Clinical Management of Lyme Disease and TickBorne Infections.” New York State Lyme and TickBorne Disease Summit, Syracuse, N.Y. Sept. 19, 2024.

Platform Presentation: Shields RK, Abbo LM, Ackley R, Aitken SL, Albrecht B, Babiker A, Cifuentes R, Claeys KC, DeSear K, Gallagher JC, Gregory E, Heil EL, Hickey C, Klatt M, Kline EG, Kubat RC, Kufel WD, Lee JG, Lim A, Lingg T, MacDougall C, Mathers A, McCreary EK, Moore WJ, Olson S, Oxer J, Pearson JC, Pham C, Polk C, Satlin MJ, Satola SW, Shah S, Solanki YB, Tamma P, Vega A, Veena V, Veve MP, Wangchinda W, Witt LS, Wu J, Pogue JM. “Defining the magnitude of desirability of outcome ranking (DOOR) differences in effectiveness of Ceftazidime-Avibactam (CZA) versus CeftolozaneTazobactam (C/T) for multidrug-resistant (MDR)

Pseudomonas aeruginosa infections in the United States (CACTUS).” IDWeek 2024, Los Angeles, Calif. Oct. 18, 2024.

Platform Presentation: Shields RK, Abbo LM, Ackley R, Aitken SL, Albrecht B, Babiker A, Cifuentes R, Claeys KC, DeSear K, Gallagher JC, Gregory E, Heil EL, Hickey C, Klatt M, Kline EG, Kubat RC, Kufel WD, Lee JG, Lim A, Lingg T, MacDougall C, Mathers A, McCreary EK, Moore WJ, Olson S, Oxer J, Pearson JC, Pham C, Polk C, Satlin MJ, Satola SW, Shah S, Solanki YB, Tamma P, Vega A, Veena V, Veve MP, Wangchinda W, Witt LS, Wu J, Pogue JM. “Impact of Patient Subgroups on the Efficacy of Ceftazidime-Avibactam (CZA) versus CeftolozaneTazobactam (C/T) for Multidrug-resistant (MDR)

Pseudomonas aeruginosa infections in the United States (CACTUS).” IDWeek 2024, Los Angeles, Calif. Oct. 18, 2024.

Platform Presentation: Kufel WD (Moderator), Bollyky PL (Moderator). “New Therapies for Bad Bugs.” IDWeek 2024, Los Angeles, Calif. Oct. 19, 2024.

Platform Presentation: Kufel WD, Hanrahan KD, Seabury RW, Parsels KA, Gallagher JC, MacDougall C, Covington EW, Chahine EB, Britt RS, Steele JM. “Let’s Have a Chat: How Well Does an Artificial Intelligence Chatbot Answer Clinical Infectious Diseases Pharmacotherapy Questions?” IDWeek 2024, Los Angeles, Calif. Oct. 19, 2024.

Platform Presentation: Buyukyanbolu E, Argotsinger J, Beck ET, Chamberland RR, Clark AE, Daniels AR, Liesman R, Gialanella P, Hand J, Harrington AT, Humphries RM, Huse H, Loeb M, Sears A, Kufel WD, Riddell SW, Marino J, Westblade LF, Mochon AB, Narayanan N, Kirn TJ, Pierce VM, Potula R, Tekle T, Simner PJ, Tibbetts RJ, Vu C, Abbo LM, Martinez O, Nicolau DP, Asempa TE. “Activity of Sulbactam-durlobactam and Standard-of-Care Antibiotics against Acinetobacter baumannii-calcoaceticus complex isolates acquired from Hospitalized Patients in the United States (2023 – 2024).” IDWeek 2024, Los Angeles, Calif. Oct. 19, 2024.

Platform Presentation: Kufel WD, Farrar JE. “Therapeutic Debates 2024. Safety Showdown: Analyzing Vancomycin and Piperacillin-Tazobactam versus Vancomycin and Cefepime in Antibiotic

Regimens.” American Society of Health-System Pharmacists Midyear Clinical Meeting 2024, New Orleans, La. Dec. 9, 2024.

Platform Presentation: Kufel WD, Darko W. “Management Case Study: Development and Implementation of a Clinical Research Microcredential Program for Pharmacy Residents.” American Society of Health-System Pharmacists Midyear Clinical Meeting 2024, New Orleans, La. Dec. 9, 2024.

Platform Presentation: Kufel WD, Hanrahan KD, Seabury RW, Parsels KA, Gallagher JC, MacDougall C, Covington EW, Chahine EB, Britt RS, Steele JM. “Let’s Have a Chat: How Well Does an Artificial Intelligence Chatbot Answer Clinical Infectious Diseases Pharmacotherapy Questions?” New York State Council of Health-System Pharmacists Annual Assembly, Saratoga Springs, N.Y. April 4, 2025.

Platform Presentation: Volk CE, Kufel WD, Hutson P, Mahapatra R, Rose WE. “Monthly Dalbavancin Dosing for Suppressive Therapy: A Case Series and Pharmacokinetic Estimation Analysis.” Oral Abstract Presentation. European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria. April 15, 2025.

Emily Leppien, PharmD

Platform Presentation: Leppien EE and Lyman TA. “Binghamton University’s Substance Use Disorder Interprofessional Education Pilot Project: Key Findings and Future Opportunities.” National Academy of Medicine’s 3Cs Core Competency Implementation Final Convening, Washington, D.C. December 2024.

Platform Presentation: Geiger JE, Leppien EE. “I40 Alternatives to Opioids for Older Adults.” APhA Annual Meeting and Exposition, Nashville, Tenn. March 2025.

Platform Presentation: Franko TS, Garofoli MP, Leppien EE, Pals HE. “Let’s Get Chatty About Controlled Substance Concerns.” APhA Annual Meeting and Exposition, Nashville, Tenn. March 2025.

Mia Lussier, PharmD

Poster Presentation: Lussier ME, Beedle AM, Leppien EE, Lynch SE, Rattinger GB.

“Strengthening faculty and staff success through professional development and leadership opportunities.” American Association of Colleges of Pharmacy Annual Meeting, Boston, Mass. July 2024.

Sarah Lynch, PharmD

Poster Presentation: Ilevbare P, Pernice A, Ferraloro R, Sia I, Mortelliti C, Zhang J, Skolnick K, Lau J, Lynch S, Steinberg J. “NYS Comprehensive Contraceptive Coverage Act: Extended-Quantity OCP Pack Prescribing.” Family Medicine Education Consortium, September 2024.

Poster Presentation: Bartlett T, Linerode A, Lukan N, Roger J, Shen P, and Lynch S. “Availability of Pharmacist-Dispensed Hormonal Contraceptives in New York State 6 Months Post-Implementation.” American Society of Health Systems Pharmacists, December 2024.

Platform Presentation: Lynch S. “All About Opill: The OTC Birth Control Pill.” Continuing education, one credit hour. CEI in collaboration with Binghamton University Office of Experiential Education, July and August 2024.

Kenneth McCall, PharmD

Poster Presentation: Falco BM, Fleck KK, Govel JC, Nasta GN, Zheng SR, McCall KL, Leppien EE, Piper BJ. “Second Generation Antipsychotic-Associated Serious Adverse Events in Women: An Analysis of a National Pharmacoepidemiologic Database.” ASHP Midyear Clinical Meeting and Exhibition. New Orleans, La. December 2024.

Melissa Morales, PhD

Poster Presentation: King M, Spathis R, Bagley E, Morales M. “Increased RAGE Expression in Myositis.” American College of Rheumatology. Washington, D.C. November 2024.

Poster Presentation: Xinyu J, Spathis R, Bagley E, Nagaraju K, Morales M. “Investigating the Role of Type 1 Interferon in Capillary Damage: Implications for Myositis.” American Society of Health-System Pharmacists, New Orleans, La. December 2024.

Kanneboyina Nagaraju, PhD

Invited speaker: Nagaraju K. “Standard operating procedures & good laboratory practices.” Boston, Mass. Oct. 31, 2024.

Invited speaker: Nagaraju K. Therapeutic Advisory Committee for TREAT-NMD Review Meeting. Boston, Mass. Nov. 4-5, 2024.

Invited speaker: Nagaraju K. The Brain Tumour Research Novel Therapeutics Accelerator. Boston, Mass. Nov. 6-8, 2024.

Invited speaker: Nagaraju K. “Standardizing readout of expression in Aon.” Duchenne Healthcare Professionals Summit. San Diego, Calif. Jan. 16, 2025.

Invited speaker: Nagaraju K. The Brain Tumour Research Novel Therapeutics Accelerator. Edinburgh, UK. May 20-22, 2025

Invited speaker: Nagaraju K. Department of Pharmacy Drug Sciences, Università degli Studi di Bari. Bari, Italy. May 26-27, 2025

Invited speaker: Nagaraju K. “New pathological mechanisms in myositis.” XXV AIM National Congress. Taormina, Italy. May 29, 2025

Erin Pauling, PharmD

Platform Presentation: Pauling EE. “From Carbs to Capsules: Student Logs That Matter! Referred PharmTalk: Inspiring Innovative Pharmacy Education Models.” Presentation at APhA Annual Meeting (0.75 contact hours), Nashville, Tenn. March 23, 2025.

Gail Rattinger, PharmD, PhD

Poster Presentation: Herd RC, Mills M, Hammond AG, Gonzalez HL, Drewel M, Rattinger GB, Tschanz JT. “Cognitive Complaint, Mild Cognitive Impairment, and Mild Behavioral Impairment as Predictors of Dementia or Alzheimer’s Disease in a Population-Based Sample: The Cache County Study.” Alzheimer’s Association International Conference (AAIC), Philadelphia, Penn. July 28–Aug. 1, 2024.

Poster Presentation: Murray J, Krause L, Schwartz S, Rattinger GB, Crowley SL, Tschanz JT, DeBerard MS. “Predictors of Prescription Opioid and Prescription Stimulant Misuse in College Students.” Society of Behavioral Medicine (SBM) 46th Annual Meeting and Scientific Sessions, San Francisco, Calif. March 26-29, 2025.

Eric Richards, BS Pharm

Platform Presentation: Richards E. “High Reliability Organizations (HROs) and Medication Safety.” Continuing education, one credit hour. Southern Tier Society of Health-system Pharmacists, Johnson City, N.Y. October 2024.

Yuanjun Shen, PhD

Poster Presentation: Shen Y, Lin D, Saiyed A. “Vps34 Activation Is Pulmonary Vascular Smooth Muscle Cell-specific and Akt-dependent in Pulmonary Arterial Hypertension. InC26. Unraveling the Gordian Knot: Multi-Dimensional OMICs and Signaling Motifs in Pulmonary Vascular Disease.” 2025 American Thoracic Society International Conference. San Francisco, Calif. May 2025 (pp. A4670-A4670).

Sarah Spinler, PharmD

Poster Presentation: Govel J, Spinler SA, Kufel WD. “Board Certification Exposure and Awareness Among Doctor of Pharmacy Programs.” American College of Clinical Pharmacy (ACCP) Annual Meeting, Phoenix, Ariz. October 2024.

Poster Presentation: Naik H, Kufel WS, Spinler SA. “Impact of Capstone Research Experience on Doctor of Pharmacy Post-graduate Work Roles.” American College of Clinical Pharmacy Annual Meeting, Phoenix, Ariz. Nov. 14, 2024.

Poster Presentation: Govel J, Spinler SA, Kufel WD. “Board Certification Exposure and Awareness Among Doctor of Pharmacy Programs.” American College of Clinical Pharmacy Annual Meeting, Phoenix, Ariz. Nov. 14, 2024.

Platform Presentation: Spinler SA. “AC.CVS.03: Geriatric Journeys in Cardiology: Navigating ACS Management Beyond Conventional Guidelines!” Panelist. American Heart Association Scientific Sessions, Chicago, Ill. Nov. 16, 2024.

Platform Presentation: Spinler SA. Moderator: “Networking Session Challenges and Opportunities for Pharmacy Practice Faculty in Professional Practice Settings.” American Society of HealthSystem Pharmacists Midyear Clinical Meeting, New Orleans, La. Dec. 8, 2024.

Platform Presentation: Spinler SA. Moderator: “Research and Researchers Networking Session.”

American Society of Health-System Pharmacists Midyear Clinical Meeting, New Orleans, La. Dec. 8, 2024.

Platform Presentation: Spinler SA. Meeting Planner and Moderator: “Jump Start Research in Practice.” National Virtual Networking Session hosted by the ASHP Section of Pharmacy Educators in partnership with the ASHP Foundation, May 13, 2025.

Platform Presentation: Panelist: “Atrial Fibrillation Management: Cardio-oncology.” American College of Cardiology ACC.25, Chicago, Ill. March 29, 2025.

L. Nathan Tumey, PhD

Poster Presentation: Mullapudi M, Zhang A, McKay S, Brooks T, Tumey LN. “Discovery of a novel Trop2targeting immune-stimulating antibody conjugate with efficacy in pancreatic cancer models.” Chicago, Ill. April 25-30, 2025.

Platform Presentation: Tumey LN. “Immune stimulating antibody conjugates: An overview.” Invited speaker, ADC World Summit, San Diego, Calif. Nov. 4-7, 2024.

Platform Presentation: Tumey LN. “New directions in immune-modulating antibody conjugates.” Invited speaker, U. Michigan, Feb. 11-12, 2025.

Platform Presentation: Tumey LN. “The magic of legumain cleavable peptides: New ADC linker designs for diverse applications.” Invited speaker, 17th Winter Conference on Medicinal & Bioorganic Chemistry, Steamboat Springs, Colo. Feb. 2-6, 2025.

Platform Presentation: Yaseen A, Tumey LN. “Legumain cleavable linker for the release of Ultrapotent Glucocorticoids for immunosuppressive antibody-drug conjugates.” ACS National Meeting, San Diego, Calif. March 27, 2025.

Platform Presentation: Benjamin S, Tumey LN. “Synthesis and optimization of PMO Antibody conjugate with improved penetration.” ACS National Meeting, San Diego, Calif. March 23, 2025.

Platform Presentation: Tumey LN. “ADC Design Workshop.” Invited speaker, Protein Engineering Summit (PEGS), Boston, Mass. May 2025.

Tao Zhang, PhD

Poster Presentation: Mans J, Zhang T, Dong X. “Development and characterization of solid amphotericin B granules to enhance oral bioavailability.” 2024 Controlled Release Society Annual Meeting & Exposition. Bologna, Italy. July 8-12, 2024.

Poster Presentation: Dash SK, Rahman MA, Yi B, Williams B, Lim GS, Zhou S, Zou P, Li Y, Mahler G, Zhang T. “Microfluidic Blood-Milk Barrier and Physiologically Based Pharmacokinetic Model to Predict Lofexidine Secretion into Breast Milk.” 2024 American College of Clinical Pharmacology (ACCP) Annual Meeting, Bellevue, Wash. Sept. 8-10, 2024. (Mohammad Asikur Rahman recognized as ACCP Student & Trainee Abstract Award Winner).

Poster Presentation: Qian L, Zhang T, Dihn J, Paine M, Zhou Z. “Physiologically Based Pharmacokinetic Modeling of Cannabidiol (CBD), Δ-9-Tetrahydrocannabinol (THC), and Their Active Metabolites in Healthy Adults After Administration of CBD and THC by Multiple Routes.” 26th North American ISSX and 39th JSSX Meeting, Honolulu, Hawaii, Sept. 15-18, 2024.

Poster Presentation: Zhao Z, Zou P, Fang Y, Zhang T. “Machine Learning Approaches for Assessing Medication Transfer to Human Breast Milk: Estimating Milk/Plasma Drug Ratios.” 2024 American Association of Pharmaceutical Scientists (AAPS) PharmSci 360, Salt Lake City, Utah, Oct. 20-23, 2024.

Poster Presentation: Dash SK, Rahman MA, Yi B, Williams B, Lim GS, Zhou S, Zou P, Li Y, Mahler GJ, Zhang T. “A Mammary Epithelium on a Chip for Assessing Lofexidine Transport into Breast Milk.” 2024 Biomedical Engineering Society (BMES) Annual Meeting, Baltimore, Md. Oct. 23-26, 2024.

Bofang Yi, G2 student

Tao Zhang as mentor

Poster Presentation: Yi B, Chen S, Rahman MA, Bae SH, Bashar M, Zhao Z, Zhang T. “A PBPK Model for Prediction of Apixaban and Rivaroxaban Secretion into Milk.” 2024 American Association of Pharmaceutical Scientists (AAPS) PharmSci 360, Salt Lake City, Utah, Oct. 20-23, 2024.

The School of Pharmacy and Pharmaceutical Sciences’ Class of 2029 participates in the 2025 White Coat Ceremony.

Grant Funding

Jared Bagley

$576

Intersecting genetic risk for extreme cocaine self-administration with dopamine neurotransmission

National Institute on Drug Abuse

$248,999

Intersecting genetic risk for extreme cocaine self-administration with dopamine neurotransmission

National Institute on Drug Abuse

L. Nathan Tumey/Samantha Benjamin (student)

$25,789

Mitigating ADA Through Site-specific Conjugation Technology

National Institute of General Medical Sciences

Tracy Brooks

$5,000

AFPE Pre-Doctoral Fellowship in Pharmaceutical Sciences

American Foundation Pharmaceutical Education

Yuan Fang

$29,500

Understanding the molecular basis for corticosteroids efficacy in DMD: Identifying partial correlations network across lipidomic, proteomic, and moto function profiles using Vamorolone VBP 15*004 clinical trial data

Foundation to Eradicate Duchenne

John Fetse

$1,000

Development of Smart Drug Delivery Systems for Prostate Cancer Immunotherapy

American Association of Colleges of Pharmacy

Yetrib Hathout

$16,084

Materials Testing Agreement Between The Research Foundation for the State University of New York and DHPS Foundation Agreement #FP13039/16651

DHPS Foundation

$12,725

Pilot Trial of Vamorolone for the Treatment of Becker Muscular Dystrophy

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Wesley Kufel

$5,000

Board Certification Exposure and Awareness Among United States Doctor of Pharmacy Programs

Board of Pharmacy Specialties

Yanyan Li

$50,000

Nanoscale exosomes from broccoli sprouts improve the targeted delivery and therapeutic efficacy of bioactives against inflammatory bowel disease

USDA National Institute of Food and Agriculture

Mia Lussier

$2,750

Impact of Pharmacy Closures in Broome County on Patients and Pharmacy Staff

American Association of Colleges of Pharmacy

Kuo-Ching Mei

$385,660

Complementary Biotherapeutic Delivery Platforms for Enabling Gene Re-delivery

National Institute of General Medical Sciences

Melissa Morales

$132,808

Drug repurposing in DMD: Efficacy of IL-17A receptor blockade alone and in combination with Vamorolone in a mouse Foundation to Eradicate Duchenne

Yuanjun Shen

$246,467

Vascular Smooth Muscle Vps34 in Pulmonary Arterial Hypertension

National Heart, Lung, and Blood Institute

L. Nathan Tumey

$25,000

Free Drug Release from ADCs dosed in mice

Synthis Therapeutics

$42,448

STEAP1 ADCs for treatment of cancer

Oslo University Hospital

$40,294

Mitigating ADA Through Site-specific Conjugation Technology

National Institute of General Medical Sciences

$45,000

TAF 2024: Validation of Novel Antibody Drug Conjugates for the Treatment of Cancer

Corporate Funded

$303,056

Legumain to the rescue: A new ADC linker strategy to address the limitations of cathepsin cleavage

National Institute of General Medical Sciences

Tao Zhang

$8,054

Novel Formulation Technology to Enhance Oral Absorption of Waterinsoluble Drugs

National Institutes of Health

$448,182

A Novel Physiologically Based Pharmacokinetic (PBPK) Modeling Approach to Facilitate Safer Medications During Lactation

National Institute of Child Health and Human Development

Students learn to mix medicine in the Compounding Lab at the School of Pharmacy and Pharmaceutical Sciences.

SOPPS Faculty Achievement Highlights

Kelly Bach

• AACP Secretary of Knowledge Management

KarenBeth Bohan

• Co-chair, Promoting Scholarship in Pharmaceutical Education of the Academic Pharmacy Section of FIP

Taylor Clark

• NYSCHP Southern Tier PresidentElect

Leon Cosler

• Research APPE Preceptor of the Year Award

Judith DeLuca

• AACP COD Standard of Care and its Role in Practice Transformation Taskforce

Elizabeth Hageman

• Lois B. DeFleur International Innovation Fund Award

• Services for Students with Disabilities Award

Anthony Hopkins

• NYSCHP Southern Tier Secretary

Wesley Kufel

• Elected Fellow of ACCP (FCCP)

• Elected Fellow of Infectious Diseases Society of America (FIDSA)

• 2024 Outstanding Reviewer Award from JACCP

• 2025 NYSCHP Excellence in Completed Research Award

• Chair of BCIDP Specialty Council

• Appointed to the editorial board of JACCP

• Dean’s Award for Pharmacy Practice Scholarship

Emily Leppien

• 2024 Provost’s Award for Excellence in Interprofessional Education

• Nominated to serve on the Society of Pain and Palliative Care Pharmacists (SPPCP) Board of Trustees

Rachel Lucas

• 2025 Provost’s Award for Excellence in Interprofessional Education

• NYSCHP Southern Tier Past-President

• NYS ACCP Past-President

• Dean’s Award for Faculty Service

Mia Lussier

• NYS ACCP 2024 Researcher of the Year

Sarah Lynch

• NASPA Excellence in Innovation Award

• Excellence in Capstone Research Silver Award

Kenneth McCall

• Vice President of the Partnership for Safe Medicines

• Department of Pharmacy Practice Teacher of the Year for the class of 2025

• Excellence in Capstone Research Gold Award

Erin Pauling

• Inducted as a Fellow of APhA (FAPhA)

• NYS ACCP 2024 Educator of the Year

• Dean’s Award for Teaching Innovation

Eric Richards

• NYSCHP Southern Tier President

Sarah Spinler

• 2024 ACCP Clinical Practice Award

• AHA Scientific Statement Writing Panel on Risk Stratification and Management of Left Ventricular Injury in Ischemic Stroke Prevention

• Named to the ASHP Research Advisory Council

Publications

Journal Articles

Ahmet A, Tobin R, Dang UJ, Rooman R, Guglieri M, Clemens PR, Hoffman EP, Ward LM. Adrenal suppression from vamorolone and prednisone in Duchenne muscular dystrophy: results from the phase 2b clinical trial. J Clin Endocrinol Metab. 2024 Aug 4:dgae521. doi: 10.1210/clinem/dgae521. Epub ahead of print. PMID: 39097643.

Alaba, T., Zhang, T. , Li, Y., and Ishaq, S. Steamed broccoli sprouts diet alleviates inflammatory bowel disease by increasing anti-inflammatory, antioxidant, and gut protective metabolites in an ulcerative colitis mouse model. Functional Foods in Health and Disease, 15(5):272-295. DOI10.31989/ ffhd.v15i5.1603

Benneh CK, Abotsi WKM, Mante PK, Biney RP, Fetse JP, Abeka MK, Adongo DW, Woode E. Evidence for the anxiolytic- and antidepressant-like effects of three semi-synthetic derivatives of xylopic acid in mice. Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan 28. doi: 10.1007/s00210-025-03814-8. Epub ahead of print. PMID: 39873715.

Bohan KH, Nambatya W, Nicol MR, Eneh P, Phyu S, Adome RO. Phenytoin dosing practices for traumatic brain injury seizure prophylaxis in the absence of the availability of therapeutic drug monitoring in Uganda: a chart review study. African Journal of Pharmacy and Pharmacology. 2025, 19(3):25-35.

Caniff KE, Rebold N, Xhemali X, Tran N, Eubank TA, Garey KW, Guo Y, Chang M, Barber KE, Krekel T, Biagi M, Kufel WD, Carr A, Hayes J, Carlson TJ, Frens J, Venugopalan V, Lucas K, Kunz Coyne AJ, Sanders J, Chandler E, Li R, Antosz K, Justo JA, Benefield R, Moore WJ, Ross J, Adams J, Albarillo F, Stefanos S, Hobbs ALV, Mercuro N, Raux B, Zeitler K, Rybak MJ. Real-World Applications of ImipenemCilastatin-Relebactam: Insights From a Multicenter Observational Cohort Study. Open Forum Infect Dis. 2025 Feb 26;12(4):ofaf112. doi: 10.1093/ofid/ofaf112. PMID: 40212030; PMCID: PMC11983095.

Cao Y, Salvati LR, Chen J, Ragab A, Mez J, Satizabal CL, Alosco ML, Fang Y, Qiu WQ, Lunetta KL, Murabito JM, Doyle MF. The Association of Circulating Immune Cells with Cognitive Function, Brain Imaging, and Incident all-cause and Alzheimer’s Dementia: The Framingham Offspring Study. J Gerontol A Biol Sci Med Sci. 2025 Apr 1:glaf067. doi: 10.1093/gerona/glaf067. Epub ahead of print. PMID: 40168089.

Chen J, Ragab AAY, Doyle MF, Alosco ML, Fang Y, Mez J, Satizabal CL, Qiu WQ, Murabito JM, Lunetta KL. Inflammatory protein associations with brain MRI measures: Framingham Offspring Cohort. Alzheimers Dement. 2024 Nov;20(11):7465-7478. doi: 10.1002/alz.14147. Epub 2024 Sep 16. PMID: 39282876; PMCID: PMC11567832.

Coli KG, Yuksel JM, McCall KL, Guan J, Ulen KR, Noviasky J. Utilization of Lower-Dose Cyclobenzaprine in the Older Inpatient. Sr Care Pharm. 2024 Jul 1;39(7):249-258. doi: 10.4140/ TCP.n.2024.249. PMID: 38937891.

Cordeiro-Santanach A, Morales F, Parquet MDC, Uaesoontrachoon K, Rowsell J, Warford J, Wu W, Elustondo P, Hoffman EP, Nagaraju K. The effect of IL-1β inhibitor canakinumab (Ilaris®) on IL-6 production in human skeletal muscle cells. PLoS One. 2025 Mar 6;20(3):e0316110. doi: 10.1371/ journal.pone.0316110. PMID: 40048444; PMCID: PMC11884680.

Cosler LE, Midence L, Hayes JJ, Gondeck JT, Moy K, Chen MH, Hogan JD. The Influence of State Restrictions on Opioid Prescribing: 2006-2018. J Public Health Manag Pract. 2024 Sep 24. doi: 10.1097/PHH.0000000000002004. Epub ahead of print. PMID: 39321427.

Dai W, Fang Y, Subedi S. Mixtures of logistic normal multinomial regression models for microbiome data. J Appl Stat. 2024 Aug 1;52(3):624-655. doi: 10.1080/02664763.2024.2383286. PMID: 39950023; PMCID: PMC11816629.

Dash SK, Rahman MA, Yi B, Williams B, Lim GS, Zhou S, Zou P, Li Y, Mahler GJ, Zhang T. Microfluidic blood-milk barrier and physiologically based pharmacokinetic model to predict lofexidine secretion into breast milk. J Pharm Sci. 2025 Mar 19;114(6):103767. doi: 10.1016/j.xphs.2025.103767. Epub ahead of print. PMID: 40113090.

Davis MR, Kufel JE, Kufel WD, McCreary EK, Oleksiuk LM, Ours R, Pham CU, Ross JK, Smith EA, Trisler MJ, Tverdek F. You’ve Got a Friend in Me: Curbside Questions Infectious Diseases Clinicians Ask Infectious Diseases Pharmacists. Clin Infect Dis. 2025 May 15:ciaf250. doi: 10.1093/cid/ciaf250. Epub ahead of print. PMID: 40373198.

DeLuca J, Ference K, Lewis TL, Mielczarek M. A mixed methods study of a competency-driven approach in a pharmacy course. Pharmacy Education 2025 Mar 30:25(1):283–292. https://doi. org/10.46542/pe.2025.251.283292

Dressler A, Seabury RW, Darko W, Kufel WD, Steele JM, Kelly C, Andrew R, Hayes Z, Miller CD, Parsels KA. Nationwide Survey to Characterize and Compare the Research Experiences of American Society of HealthSystem Pharmacists-Accredited Postgraduate Year One Pharmacy Residency Programs. J Pharm Pract. 2024 Aug 21:8971900241273223. doi: 10.1177/08971900241273223. Epub ahead of print. PMID: 39165184.

Fang Y, Chen J, Mez J, Satizabal CL, Alosco ML, Qiu WQ, Doyle MF, Murabito JM, Lunetta KL. Modeling heterogeneity in cognitive trajectories in the Framingham Heart Study. Front Aging Neurosci. 2025 Jun 25;17:1471154. doi: 10.3389/ fnagi.2025.1471154. PMID: 40636900; PMCID: PMC12238755.

Fang Y, Dang UJ, Illei KI, Clemens P, Hoffman EP; as the CINRG, VISION DMD Investigators. Association of DMD Gene Variant Classes With Motor Outcomes in a Drug Registration Clinical Trial Setting. Neurol

Genet. 2025 Feb 26;11(2):e200251. doi: 10.1212/ NXG.0000000000200251. PMID: 40017558; PMCID: PMC11867578.

Fera T, Burnett A, Grandoni J, Moore MR, Nussbaum BB, Pollack CV Jr, Rose AE, Spinler SA, Streiff MB, Turck CJ, Fanikos J. Development of a Medication-Use Evaluation Template for Andexanet Alfa in the Reversal of Anticoagulation With Factor Xa Inhibitors. J Pharm Pract. 2024 Jul 20:8971900241263164. doi: 10.1177/08971900241263164. Epub ahead of print. PMID: 39030931.

Govel JC, Seabury RW, Asiago-Reddy EA, Gutierrez RL, Parsels KA, Kufel WD. Evaluation of shorter versus longer antifungal treatment durations for Candida spp. urinary tract infections among hospitalized adults. Antimicrob Agents Chemother. 2025 Apr 22:e0192024. doi: 10.1128/aac.01920-24. Epub ahead of print. PMID: 40261002.

Hoffman EP, Clemens PR, Hagerty L, Dang UJ. Some functional improvements in placebo and Delandistrogene moxeparvovec-treated trial participants explained by increased corticosteroid dosing. J Neuromuscul Dis. 2025 Jun 11:22143602251346660. doi: 10.1177/22143602251346660. Epub ahead of print. PMID: 40495560.

Hoffman EP, Kesari A. Genome Sequencing in the NICU and PICU Is Here to Stay. Neurology. 2025 Jan 14;104(1):e210267. doi: 10.1212/ WNL.0000000000210267. Epub 2024 Dec 19. PMID: 39700447.

Hoffman EP. The Persistence of Duchenne vs Becker Muscular Dystrophies: Vive la Difference? Neurol Genet. 2024 Dec 17;11(1):e200230. doi: 10.1212/NXG.0000000000200230. PMID: 39703463; PMCID: PMC11655166.

Khan AH, Bagley JR, LaPierre N, Gonzalez-Figueroa C, Spencer TC, Choudhury M, Xiao X, Eskin E, Jentsch JD, Smith DJ. Differing Genetics of Saline and Cocaine Self-Administration in the Hybrid Mouse Diversity Panel. Genes Brain Behav. 2025 Jun;24(3):e70029. doi: 10.1111/gbb.70029. PMID: 40527326; PMCID: PMC12173464.

Kim J, Nichols DA, Zhang T, Faraone SV, Radonjić NV. Managing attention-deficit/hyperactivity disorder in a breastfeeding mother: A case report. Pharmacotherapy. 2025 Jun 19. doi: 10.1002/ phar.70035. Epub ahead of print. PMID: 40536085.

Klosko RC, Whitson B, Lampert B, McLaughlin E, Orzel L. Safety of enoxaparin in patients implanted with continuous flow left ventricular assist devices. Artif Organs. 2024 Nov 27. doi: 10.1111/aor.14908. Epub ahead of print. PMID: 39601155.

Kufel WD, Hanrahan KD, Seabury RW, Parsels KA, Gallagher JC, MacDougall C, et al. Let’s Have a Chat: How Well Does an Artificial Intelligence Chatbot Answer Clinical Infectious Diseases Pharmacotherapy Questions? Open forum infectious diseases. 2024;11(11).

Kufel WD, Jeffres MN, Bland CM, Jones BM, Staicu ML, Justo JA, et al. A comprehensive survey of penicillin allergy education among United States Colleges and Schools of Pharmacy. Journal of the American College of Clinical Pharmacy. 2024.

Kufel WD, Kufel JE. Use of local treatment in managing infections: Focus on antimicrobial locks, beads, and cement. Am J Health Syst Pharm. 2024 Sep 26:zxae264. doi: 10.1093/ajhp/zxae264. Epub ahead of print. PMID: 39324594.

Kufel WD, MacDougall C, Aitken SL, Dzintars K, Davis MR, Mahoney MV, Gallagher JC. Antimicrobial Stewardship and Beyond: The Many Essential Roles of Infectious Diseases Pharmacists. Clin Infect Dis. 2025 Apr 22:ciaf106. doi: 10.1093/cid/ciaf106. Epub ahead of print. PMID: 40261039.

Kufel WD, MacDougall C, Covington EW, Gallagher JC, Seabury RW, Steele JM. Reply: “Continuing the Chat: How Can We Improve the Performance of an Artificial Intelligence Chatbot in Answering Clinical Infectious Diseases Pharmacotherapy Questions?”. Open Forum Infect Dis. 2025 Feb 6;12(2):ofaf074. doi: 10.1093/ofid/ofaf074. PMID: 39990631; PMCID: PMC11845596.

Kufel WD, Priyank K. Oral flucytosine dosing in peritoneal dialysis. Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0070024. doi: 10.1128/ aac.00700-24. Epub 2024 Jul 22. PMID: 39037242; PMCID: PMC11304716.

Kufel WD, Zagoria ZJ, Seabury RW, Zeineddine N, Thomas SJ, Spinler SA, Steele JM. Impact of Remdesivir on Heart Rate and Bradycardia Incidence Among Hospitalized Adults With COVID-19. Ann Pharmacother. 2025 Apr 23:10600280251327154. doi: 10.1177/10600280251327154. Epub ahead of print. PMID: 40269618.

Kufel WD, Zeineddine N, Fouad A, Roenfanz HF, Shields RK, Kline EG, Warner J, Hanrahan K, Kuti JL. Pharmacokinetic and pharmacodynamic evaluation of sulbactam-durlobactam in a critically ill patient on continuous venovenous hemofiltration infected with carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex. Pharmacotherapy. 2025 May 15. doi: 10.1002/ phar.70027. Epub ahead of print. PMID: 40371868.

Lam H, Parsels K, Steele JM, Kufel WD, Andrew R, Miller C, Darko W, Seabury R. Utilization of the PEN-FAST Clinical Decision-Making Tool to Update Penicillin Allergies and Identify Low-Risk Patients. J Pharm Pract. 2024 Nov 19:8971900241302394. doi: 10.1177/08971900241302394. Epub ahead of print. PMID: 39562507.

Lewis TL, DeLuca J, Ference K. Addressing systemic racism and its influence on health disparities through a foundational pharmacy course and a student-led symposium. Curr Pharm Teach Learn. 2025 Feb 26;17(5):102239. doi: 10.1016/j. cptl.2024.102239. Epub ahead of print. PMID: 40020652.

Li YT, Mei KC, Liam-Or R, Wang JT, Faruqu FN, Zhu S, Wang YL, Lu Y, Al-Jamal KT. Graphene Oxide Nanosheets Toxicity in Mice Is Dependent on Protein Corona Composition and Host Immunity. ACS Nano. 2024 Aug 20;18(33):22572-22585. doi: 10.1021/acsnano.4c08561. Epub 2024 Aug 7. PMID: 39110092; PMCID: PMC11342366.

Low CY, McCall KL, Piper BJ. Declines in Tapentadol Use in the US but Pronounced Regional Variation. Pharmacy (Basel). 2025 May 14;13(3):67. doi: 10.3390/pharmacy13030067. PMID: 40407505; PMCID: PMC12101176.

Lucas R, Govel J, Nasta G, Brooks M, Clark T, Johnston Y, Lussier M, McCall K, Rola A, Rouhana N, Seward S, McGinley J. Utilizing panel discussions

to facilitate interprofessional learning: Lessons from the rural and underserved service track. Journal of the American College of Clinical Pharmacy. 2025 Jun 27; https://doi.org/10.1002/jac5.70074

Lussier ME, Desai RJ, Wright EA, Gionfriddo MR. Impact of cost on prescribing diabetes medications for older adults with type 2 diabetes in the outpatient setting. Res Social Adm Pharm. 2024 Aug;20(8):755-759. doi: 10.1016/j. sapharm.2024.04.013. Epub 2024 Apr 26. PMID: 38697890.

McCall KL, Cabral DL, Coghlan JF, Concepcion AM, Denimarck KE, Shalumov SS. Therapeutic failure reported with HIV long-acting injectables: An analysis of the FDA Adverse Event Reporting System from 2021 to 2024. HIV Med. 2024 Sep 5. doi: 10.1111/hiv.13709. Epub ahead of print. PMID: 39234659.

McCall KL, Leppien EE, Piper BJ, Falco BM, Fleck KK, Govel JC, Nasta GN, Zheng SR. SecondGeneration Antipsychotic-Associated Serious Adverse Events in Women: An Analysis of a National Pharmacoepidemiologic Database. J Clin Psychopharmacol. 2025 Mar-Apr 01;45(2):111115. doi: 10.1097/JCP.0000000000001962. PMID: 40014466.

McCall KL, Mastro Dwyer KA, Casey RT, Samana TN, Sulicz EK, Tso SY, Yalanzhi ER, Piper BJ. Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system. Expert Opin Drug Saf. 2025 Apr 29:1-8. doi: 10.1080/14740338.2025.2499670. Epub ahead of print. PMID: 40285721.

Nasuhidehnavi A, Zarzycka W, Górecki I, Chiao YA, Lee CF. Emerging interactions between mitochondria and NAD+ metabolism in cardiometabolic diseases. Trends Endocrinol Metab. 2024 Aug 27:S1043-2760(24)00191-7. doi: 10.1016/j. tem.2024.07.010. Epub ahead of print. PMID: 39198117.

Pradhan AM, Lussier ME, Nguyen M, Voyce SJ, Wright EA. Qualitative evaluation to understand barriers and facilitators to prescribing angiotensin receptor-neprilysin inhibitors (ARNi) and sodiumglucose cotransporter inhibitors (SGLT2i) in patients with heart failure with reduced ejection fraction (HFrEF). J Am Pharm Assoc (2003). 2024 Nov-

Dec;64(6):102224. doi: 10.1016/j.japh.2024.102224. Epub 2024 Aug 28. PMID: 39209218.

Ray ME, Ellington TM, Lebovitz L, Spinler SA, Sobieraj DM, Kelsch MP, Chen AMH. Preparing NAPLEX-Ready Graduates Requires Collaboration to Optimize Success. Am J Pharm Educ. 2025 Jul;89(7):101427. doi: 10.1016/j.ajpe.2025.101427. Epub 2025 May 31. PMID: 40456486.

Romano D, Lynch S, Komor T, Rhodes-Keefe J, Collier R, Sprague LM. Exploring the Effect on Pharmacy Students’ Empathy Following a Simulation Using 360-Degree Video. Am J Pharm Educ. 2025 May;89(5):101402. doi: 10.1016/j. ajpe.2025.101402. Epub 2025 Apr 2. PMID: 40185312.

Shamoon-Pour M, Canessa EH, Macher J, Fruitwala A, Draper E, Policriti B, Chin M, Nunez M, Puccio P, Fang Y, Wang XR, Hathout Y. Genomic and Proteomic Analyses of Bacterial Communities of Ixodes scapularis Ticks from Broome County, New York. Microorganisms. 2025 Jan 24;13(2):258. doi: 10.3390/microorganisms13020258. PMID: 40005625; PMCID: PMC11857480.

Shen Y, Gleghorn JP. Class III Phosphatidylinositol-3 Kinase/Vacuolar Protein Sorting 34 in Cardiovascular Health and Disease. J Cardiovasc Transl Res. 2025 Apr;18(2):392-407. doi: 10.1007/ s12265-024-10581-z. Epub 2025 Jan 16. Review. PubMed PMID: 39821606; PubMed Central PMCID: PMC12043424.

Shen Y. Will Stub1 Be the Next Target for Pulmonary Hypertension Therapy Development?. Am J Respir Cell Mol Biol. 2025 Mar 5. doi: 10.1165/rcmb.20250034ED. [Epub ahead of print] PubMed PMID: 40042807.

Shields RK, Abbo LM, Ackley R, Aitken SL, Albrecht B, Babiker A, Burgoon R, Cifuentes R, Claeys KC, Curry BN, DeSear KE, Gallagher JC, Golnabi EY, Gross AE, Hand J, Heil EL, Hornback KM, Kaye KS, Khuu TV, Klatt ME, Kline EG, Kubat RC, Kufel WD, Lee JH, Lepak AJ, Lim A, Ludwig JM, Macdougall C, Majumdar A, Mathers AJ, McCreary EK, Miller WR, Monogue ML, Moore WJ, Olson S, Oxer J, Pearson JC, Pham C, Pinargote P, Polk C, Satlin MJ, Satola SW, Shah S, Tamma PD, Tran TT, van Duin D, VanNatta M, Vega A, Venugopalan V, Veve MP, Wangchinda W, Witt LS, Wu JY, Pogue JM;

PRECEDENT Network. Effectiveness of ceftazidimeavibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study. Lancet Infect Dis. 2024 Dec 16:S1473-3099(24)00648-0. doi: 10.1016/S1473-3099(24)00648-0. Epub ahead of print. Erratum in: Lancet Infect Dis. 2025 Jan 8:S1473-3099(25)00004-0. doi: 10.1016/S14733099(25)00004-0. PMID: 39701120.

Slick RA, Sutton J, Haberman M, O’Brien BS, Tinklenberg JA, Mardikar A, Prom MJ, Beatka M, Gartz M, Vanden Avond MA, Siebers E, Mack DL, Gonzalez JP, Ebert AD, Nagaraju K, Lawlor MW. High mobility group box 1 (HMGB1) is a potential disease biomarker in cell and mouse models of Duchenne muscular dystrophy. Biol Open. 2024 Sep 15;13(9):bio060542. doi: 10.1242/bio.060542. Epub 2024 Sep 5. PMID: 39158383; PMCID: PMC11391821.

Sobieraj DM, Ellington TM, Chen AMH, Kelsch MP, Lebovitz L, Spinler S, Ray ME. Evolving Standards: An Examination of NAPLEX Blueprint Changes and Implications for the Academy. Am J Pharm Educ. 2025 May;89(5):101400. doi: 10.1016/j. ajpe.2025.101400. Epub 2025 Apr 3. PMID: 40187565.

Spathis R, Kuriplach DR, Narvesen S, Eybs M, Huang K, Torres S, King M, Bagley E, Elustondo P, Lawlor MW, Nagaraju K, Morales M Enhancing AAV-microdystrophin gene therapy after repeat dosing by blocking phagocytosis. Front Immunol. 2025 Mar 3;16:1527840. doi: 10.3389/fimmu.2025.1527840. Erratum in: Front Immunol. 2025 Mar 21;16:1593193. doi: 10.3389/ fimmu.2025.1593193. PMID: 40098958; PMCID: PMC11911185.

Spurney CF, Chong J, Gordish-Dressman H, Hathout Y. Pilot study of canakinumab (Ilaris) in steroid naïve children with Duchenne muscular dystrophy demonstrates safety and exploratory changes in potential serum protein response biomarkers. J Neuromuscul Dis. 2025 May 21:22143602251319177. doi: 10.1177/22143602251319177. Epub ahead of print. PMID: 40396427.

Stanton J, Gionfriddo MR, Rattinger GB, Fang Y, Lussier ME. Tools for clinical pharmacists to identify medications that can cause drug-induced cognitive impairment: A systematic review. Journal

of the American College of Clinical Pharmacy. 2024;7(12):1207-27. doi.org/10.1002/jac5.2049

Szybowska PE, Nasuhidehnavi A, Lee CF. Heartbreak to immune breakdown: myocardial infarction is causing thymic injury mediated by activation of the hypothalamus-pituitaryadrenal axis. Am J Physiol Heart Circ Physiol. 2024 Aug 1;327(2):H518-H520. doi: 10.1152/ ajpheart.00473.2024. Epub 2024 Jul 19. PMID: 39028278.

Tejeda-Muñoz N, Binder G, Mei KC. Emerging therapeutic strategies for Wnt-dependent colon cancer targeting macropinocytosis. Cells Dev. 2024 Dec;180:203974. doi: 10.1016/j.cdev.2024.203974. Epub 2024 Nov 9. PMID: 39528157.

Uttaro E, Hopkins A, Kokanovich K, Maynard K, Vella M, Jones CMC, et al. Feasibility of trauma video review for the collection of medicationrelated information for research and quality improvement. American Journal of Health-System Pharmacy. 2024.

Valiuska S, Elder KK, McKay SJ, Ciudad CJ, Noé V, Brooks TA. Combinatorial Anti-Cancer Effect of Polypurine Reverse Hoogsteen Hairpins against KRAS and MYC Targeting in Prostate and Pancreatic Cancer Cell Lines. Genes (Basel). 2024;15(10).

Wei PS, Thota N, John G, Chang E, Lee S, Wang Y, Ma Z, Tsai YH, Mei KC. Enhancing RNA-lipid nanoparticle delivery: Organ- and cellspecificity and barcoding strategies. J Control Release. 2024 Sep 18;375:366-388. doi: 10.1016/j. jconrel.2024.08.030. Epub ahead of print. PMID: 39179112.

Wijekoon N, Gonawala L, Ratnayake P, Dissanayaka P, Gunarathne I, Amaratunga D, Liyanage R, Senanayaka S, Wijesekara S, Gunasekara HH, Vanarsa K, Castillo J, Hathout Y, Dalal A, Steinbusch HWM, Hoffman E, Mohan C, de Silva KRD. Corrigendum to “Integrated genomic, proteomic and cognitive assessment in Duchenne Muscular Dystrophy suggest astrocyte centric pathology” [Heliyon Volume 9, Issue 8, August 2023, Article e18530]. Heliyon. 2025 Apr 14;11(9):e43326. doi: 10.1016/j.heliyon.2025.e43326. Erratum for: Heliyon. 2023 Jul 25;9(8):e18530. doi: 10.1016/j.heliyon.2023. e18530. PMID: 40535240; PMCID: PMC12134616.

Wijekoon N, Gonawala L, Ratnayake P, Sirisena D, Gunasekara H, Dissanayake A, Amaratunga D, Steinbusch HWM, Hathout Y, Hoffman EP, Dalal A, Mohan C, de Silva KRD. Serum metabolomic signatures of patients with rare neurogenetic diseases: an insight into potential biomarkers and treatment targets. Front Mol Neurosci. 2025 Jan 10;17:1482999. doi: 10.3389/fnmol.2024.1482999. PMID: 39866907; PMCID: PMC11759312.

Wu MS, Kufel W, Riddell S, Steele J, Asiago-Reddy E. Persistent methicillin-resistant Staphylococcus aureus (MRSA) nares test positivity during initial days of systemic antistaphylococcal antimicrobial therapy. Am J Infect Control. 2024 Aug 23:S01966553(24)00661-8. doi: 10.1016/j.ajic.2024.08.014. Epub ahead of print. PMID: 39182849.

Yang Y, Yi B, Zhang T. The Impact of Substance Use Disorder and Drug Transfer into Breast Milk: Implications for Maternal and Infant Health. Pharmaceutics. 2025 May 29;17(6):719. doi: 10.3390/ pharmaceutics17060719. PMID: 40574032; PMCID: PMC12196422.

Yaseen AA, Tumey LN. Advances and challenges in immunosuppressive antibody drug conjugates. Eur J Med Chem. 2025 Jul 5;291:117576. doi: 10.1016/j. ejmech.2025.117576. Epub 2025 Mar 31. PMID: 40186891.

Zhao Z, Zou P, Fang Y, Si T, Li Y, Yi B, Zhang T. Machine learning approaches for assessing medication transfer to human breast milk. J Pharmacokinet Pharmacodyn. 2025 Apr 16;52(3):25. doi: 10.1007/s10928-025-09972-9. PMID: 40240653.

Book Chapters

Klosko R, Schwier N. Acute Coronary Syndromes. In: Naplex Review Guide, 5th ed. New York: McGraw Hill Medical; 2025.

Nagaraju K, Aggarwal R and Lundberg I. Inflammatory Diseases of Muscle and Other Myopathies. Kelley’s Textbook of Rheumatology, 12th edition. Edited by Harris ED, Budd RC and Firestein GS, Elsevier publication, 2024.